Renaissance Technologies
DFTX

Renaissance Technologies’s Definium Therapeutics DFTX Stock Holding History

Renaissance Technologies’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,519
Closed -$130K – 3936
2023
Q2 		$130K Sell
36,519
-19,267
-35% -$66.5K ﹤0.01% 3411
2023
Q1 		$177K Buy
+55,786
New +$185K ﹤0.01% 3328

Other funds holding DFTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies's DFTX Position: Q3 2023 in Review

Renaissance Technologies sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 36,519 shares — an estimated $130K sold.

Renaissance Technologies first reported a position in DFTX in Q1 2023 and held it in 2 quarters. The position peaked at $177K in Q1 2023. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • Renaissance Technologies reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Renaissance Technologies sold 36,519 Definium Therapeutics shares in Q3 2023, an estimated $130K.
  • Renaissance Technologies first reported a position in Definium Therapeutics in Q1 2023 and held it in 2 quarters.
  • Renaissance Technologies's Definium Therapeutics position peaked at $177K in Q1 2023.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.